Redeye leaves a research update following Klaria Pharma’s recently published Q1 2024 report. Overall, the report did not include any surprises and was in line with our estimates. While we argue that the company needs to secure its long-term financing and anticipate a capital raise, we also see multiple potential inflection points in store for Klaria.